DTC genetic testing

01Overview and value chain

Markers: [EC: FDA 510(k) DTC pathway + EU IVDR + GDPR/EU AI Act + CN human-genetic-resources sovereignty | OECD: Biotech & health | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Direct-to-consumer (DTC) genetic testing lets individuals order a kit, mail back a saliva sample, and receive ancestry, health and pharmacogenomic reports without a prescribing physician. The US market reached about USD 980 million in 2025 and the EU market around EUR 540 million, as the industry shifted from cheap SNP-array ancestry trivia toward preventive medicine: the 2025 milestone of USD 100 whole-genome sequencing (WGS) lets consumers read all 3 billion nucleotides at 30x coverage and surface rare pathogenic variants. The stack moves from saliva to an Illumina BeadChip (600,000- 700,000 SNPs) or a NovaSeq WGS run, through BWA-MEM alignment and GATK variant calling on GRCh38, to polygenic risk scores (PRS) computed from GWAS data. Regulation is tightening: the US FDA requires 510(k) validation and CLIA/CAP labs, the EU enforces IVDR certification and GDPR/AI-Act protection of genetic data, and China bars export of citizen DNA and runs all tests on domestic MGI sequencers. The six organizations span the US pioneers (23andMe, Ancestry), EU clinical-grade players (TellmeGen, Dante Labs) and Chinese national champions (BGI, WeGene).

Key directions of DTC genetic testing:

1. SNP genotyping arrays: Illumina BeadChips read 600,000-700,000 single- nucleotide polymorphisms for cheap ancestry and trait reports.
2. Whole-genome sequencing (30x WGS): NGS reads all 3 billion bases at 30x coverage to catch rare pathogenic variants after the USD 100 genome.
3. Polygenic risk scores: machine learning sums thousands of GWAS hits into a PRS for multifactorial disease (coronary artery disease, type-2 diabetes).
4. Pharmacogenomics and clinical gating: drug-response profiling plus telemedicine gatekeeping of pathogenic findings (BRCA1/2, LDLR).

Sectoral value chain

[saliva kit (B2C)] ──> [DNA extraction] ──> [SNP array / 30x WGS]
                                                    │
                                          (BWA-MEM + GATK + GWAS/PRS)
                                                    │
                                                    ▼
[telemedicine consult] <─── [clinical report] <─── [variant calling]

Value chain levels

Cross-cutting technologies of the sector:

• snp-genotyping-arrays: Illumina BeadChips with 600,000-700,000 probes that hybridize genomic DNA and read genotype at each SNP by laser fluorescence.
• whole-genome-sequencing-30x: NGS reading of all 3 billion bases at average 30x coverage so each nucleotide is read about 30 times to suppress sequencer error.
• polygenic-risk-scores: machine-learning aggregation of thousands of GWAS-identified SNP effects into a single relative-risk score for multifactorial disease.

02US

The United States anchors the DTC market and its FDA regulatory framework, hosting the pioneer consumer brands and the shift toward WGS.

23andMe restructuring, Ancestry genealogy, FDA 510(k) gating

• 23andMe: the DTC pioneer whose opt-in DNA database passed 15 million profiles and funded a drug-discovery arm; after a voluntary Chapter 11 process in March 2025 and a court-supervised sale, it continues ordinary operations under restructured ownership, holding prior FDA 510(k) authorizations for BRCA and pharmacogenomic reports.
• Ancestry (AncestryDNA, Blackstone-backed): the leading genealogy-focused DTC brand, running custom Illumina SNP arrays and CLIA-grade ancestry and cousin-matching at very large scale, with a redesigned 2026 user experience.
• FDA and FTC oversight: the FDA requires 510(k) validation for health-risk reports and the FTC polices marketing claims; Nebula Genomics and others push 30x WGS at the USD 100-genome frontier with blockchain-encrypted raw-data return.

03CN

China runs DTC testing under strict genetic-data sovereignty, on domestic MGI sequencers, with state-backed carrier screening.

BGI national sequencing, WeGene consumer genomics, gene-pool sovereignty

• BGI (founded 1999): the national genomics champion routes consumer testing through domestic MGI sequencers, having replaced imported Illumina technology, and supports state newborn and premarital carrier-screening programmes (e.g. thalassemia) under the Healthy China agenda.
• WeGene: a leading Chinese consumer-genomics brand (listed among the 2026 top-10 DTC brands alongside 23Mofang and MeGene), integrating DNA reports into WeChat lifestyle apps for diet and fitness recommendations.
• Genetic-data sovereignty: China prohibits export of any citizen biological samples or DNA data, requiring all DTC tests to run in certified domestic laboratories to protect the national gene pool.

04EU

The European Union enforces the strictest genetic-data regime (GDPR + IVDR + AI Act), consolidating the market around clinical-grade platforms.

TellmeGen pharmacogenomics, Dante Labs WGS, IVDR/GDPR compliance

• TellmeGen (Spain): a clinical-grade DTC platform offering the TellmeGen Advanced panel (around EUR 149) and the Ultra 30x WGS test that analyzes the full genome for common and rare disease risk, with pharmacogenomic drug-response reporting under IVDR.
• Dante Labs (Italy): a WGS-focused DTC leader offering 30x whole-genome sequencing at promotional pricing around EUR 169, returning raw data and customized reports to a global clientele under IVDR certification.
• GDPR + IVDR + AI Act: genetic data is treated as a top-category biometric special category, requiring multi-stage consent for any pharma data licensing and pushing the market toward certified platforms as uncertified startups exit.

05Leading companies and research institutes

06Tech stack and innovations

The stack runs from saliva chemistry through high-throughput sequencing to cloud bioinformatics.

1. SNP microarray genotyping:
   • genomic DNA from saliva is hybridized on an Illumina BeadChip whose silica beads carry complementary probes; laser scanning of fluorescent labels reads the genotype (A/A, A/G or G/G) at each of 600,000-700,000 SNP positions for cheap ancestry and trait reports.
2. NGS whole-genome sequencing (30x):
   • DNA is sheared to 350 bp fragments (Covaris), adapter-ligated and indexed, pooled 96-plex and run on an Illumina NovaSeq for about 44 hours, yielding around 3 TB of raw FASTQ at average 30x coverage across all 3 billion bases.
3. Bioinformatics and polygenic risk scoring:
   • FASTQ reads are aligned to the GRCh38 reference with BWA-MEM, variants are called with GATK HaplotypeCaller into a VCF, and GWAS-trained models sum thousands of SNP effects into polygenic risk scores; cloud GPU (Nvidia Clara) compresses per-genome alignment from about 20 hours to roughly 25 minutes.

07Value chains and production pipelines

Industrial pipeline of a 30x WGS DTC test (CLIA/CAP + IVDR compliant)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. B2C saliva kit         │ ───> │ 2. Mail-in & robotic      │
│    & QR registration      │      │    DNA extraction         │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. 30x WGS on NovaSeq     │ <─── │ 3. QC (Qubit, DIN)        │
│    (44 h, 3 TB FASTQ)     │      │    & indexed library prep │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Bioinformatics         │ ───> │ 6. Geneticist validation  │
│    (BWA-MEM, GATK, PRS)   │      │    & telemedicine release │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: B2C saliva kit and registration

The consumer orders online, spits 2 ml of saliva into a tube loaded with a nuclease-inhibiting stabilization buffer (stable from -20 C to +50 C for a year), and scans the tube QR code in a mobile app to register the sample.

Stage 2: Mail-in and robotic DNA extraction

The tube ships by medical post to a CLIA-certified lab where a robotic decapper feeds 96-well plates and a Hamilton STAR station extracts DNA on magnetic microparticles, washing away salivary proteins and eluting into TE buffer.

Stage 3: QC and indexed library preparation

DNA is quantified on a Qubit fluorometer (target above 10 ng/microlitre) and integrity-checked by DIN (reject below 7.0); it is Covaris-sheared to 350 bp, then adapter-ligated and PCR-indexed with a unique barcode for multiplexing.

Stage 4: 30x whole-genome sequencing

Ninety-six indexed libraries are pooled and loaded on an Illumina NovaSeq, which runs a synthesis-sequencing cycle for about 44 hours to generate roughly 3 TB of raw FASTQ at average 30x coverage.

Stage 5: Cloud bioinformatics and GWAS

FASTQ files are uploaded to encrypted cloud storage (AES-256) and aligned to GRCh38 with BWA-MEM; GATK HaplotypeCaller produces a VCF, and GWAS-trained models compute polygenic risk scores across roughly 150 conditions with GPU acceleration.

Stage 6: Geneticist validation and telemedicine release

A certified geneticist validates any pathogenic findings (BRCA1/2, LDLR); high-risk results are gated behind a telemedicine consult before release, and the interactive report is published to the consumer portal with optional lifestyle-update subscriptions.